Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 6/20 | 0.59 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.59 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.59 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.59 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.59 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.45 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.45 |
| ▸ | MMP2 | P08253 | 3/20 | 0.44 |
| ▸ | MMP9 | P14780 | 3/20 | 0.44 |
| ▸ | MMP8 | P22894 | 3/20 | 0.44 |
| ▸ | MMP13 | P45452 | 3/20 | 0.44 |
| ▸ | HPSE | Q9Y251 | 2/20 | 0.43 |
| ▸ | PRSS12 | P56730 | 1/20 | 0.43 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | APAF1 | O14727 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14091383 | 0.93 | HDAC6 (0.69) | HDAC6HDAC3HDAC1HDAC8HDAC2 | |
| SCHEMBL14115797 | 0.85 | HDAC6 (0.61) | HDAC6HDAC3HDAC1HDAC8HDAC2 | |
| SCHEMBL14115844 | 0.85 | HDAC6 (0.61) | HDAC6HDAC3HDAC1HDAC8HDAC2 | |
| SCHEMBL1509489 | 0.85 | HDAC3 (0.57) | HDAC6HDAC3HDAC1HDAC8HDAC2 | |
| SCHEMBL14091373 | 0.84 | HDAC6 (0.55) | HDAC6HDAC3HDAC1HDAC8HDAC2 | |
| SCHEMBL14091376 | 0.84 | HDAC6 (0.59) | HDAC6HDAC3HDAC1HDAC8HDAC2 | |
| SCHEMBL14091382 | 0.82 | HDAC6 (0.57) | HDAC6HDAC3HDAC1HDAC8HDAC2 | |
| SCHEMBL14091400 | 0.82 | HDAC6 (0.57) | HDAC6HDAC3HDAC1HDAC8HDAC2 | |
| SCHEMBL14091371 | 0.82 | HDAC6 (0.57) | HDAC6HDAC3HDAC1HDAC8HDAC2 | |
| SCHEMBL14091363 | 0.82 | HDAC6 (0.57) | HDAC6HDAC3HDAC1HDAC8HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8629147-B2 | Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION (US) | 2014-01-14 | — | — | US | disclosed |
| US-8629147-B2 | Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION (US) | 2014-01-14 | — | — | US | disclosed |
| US-20080207635-A1 | Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION | 2008-08-28 | — | — | US | disclosed |
| US-20080207635-A1 | Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207635-A1 | Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | LCK, MALT1, MYD88 | HDAC6 541/4885HDAC3 911/4885HDAC1 826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.